RC
MLTX icon

Rangeley Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Rangeley Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,000
Closed -$108K – 146
2025
Q3 		$108K Buy
+15,000
New +$782K 0.09% 110

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Rangeley Capital's MLTX Position: Q4 2025 in Review

Rangeley Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 15,000 shares — an estimated $108K sold.

Rangeley Capital first reported a position in MLTX in Q3 2025 and held it in 1 quarter. The position peaked at $108K in Q3 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

  • Rangeley Capital reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Rangeley Capital sold 15,000 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $108K.
  • Rangeley Capital first reported a position in MoonLake Immunotherapeutics in Q3 2025 and held it in 1 quarter.
  • Rangeley Capital's MoonLake Immunotherapeutics position peaked at $108K in Q3 2025.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Rangeley Capital's 13F filing for Q4 2025, filed 17 Feb 2026.